EDIT has announced an agreement with Shoreline Bio. As part of the deal, Shoreline will obtain an exclusive license to EDIT's SLEEK gene editing tech [1,2] for iPSC-derived NK cells and iPSC-derived macrophages (oncology), and a non-exclusive license for AsCas12a [3].
Per the terms, Shoreline will acquire EDIT-202 [4,5], a preclinical multiplexed edited iNK cell therapy developed by EDIT for solid tumours, another experimental iNK program, and certain related manufacturing technologies. In addition to development, commercial milestones and royalty payments, Shoreline is expected to pay EDIT an upfront payment at the close of the deal.
News 
Market Data 
Discover 
